Efficacy of subsequent-abemaciclib treatment after disease progression on palbociclib combined with endocrine therapy in patients with ER-positive HER2-negative metastatic breast cancer

被引：0
|
作者：
Seki, Hirohito
Nakai, Taketo
Shimizu, Ken
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-49
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-49
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Sakurada, Akihisa
    Kinoshita, Tetsuhiko
    Shimizu, Ken
    ANTICANCER RESEARCH, 2022, 42 (02) : 1099 - 1106
  • [2] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [3] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
  • [4] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [5] Effective sequence of endocrine therapy for ER-positive and HER2-negative metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Tashima, Rumiko
    Fujisue, Mamiko
    Nakano, Masahiro
    Toyozumi, Yasuo
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
  • [7] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [8] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [9] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Shimizu, Ken
    Higeta, Kaori
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients
    Nishimura, Meiko
    Kogawa, Takahiro
    Akaishi, Yuko
    Ogata, Misato
    Masuda, Jun
    Terada, Mitsuo
    Sakai, Hitomi
    Nozawa, Kazuki
    Kurozumi, Sasagu
    Yokoe, Takamichi
    Ozaki, Yukinori Ozaki
    Yazaki, Shu
    Onishi, Mai
    Iwasa, Tsutomu
    Onoe, Takuma
    Okumura, Yuta
    Nakayama, Sayaka
    Hagio, Kanako
    Takahashi, Yuko
    Tanino, Hirokazu
    Tsurutani, Junji
    Matsumoto, Koji
    Shimokawa, Mototsugu
    Takano, Toshimi
    CANCER RESEARCH, 2022, 82 (04)
12345